Journal
RSC MEDICINAL CHEMISTRY
Volume 11, Issue 6, Pages 665-675Publisher
ROYAL SOC CHEMISTRY
DOI: 10.1039/d0md00049c
Keywords
-
Funding
- Swiss National Science Foundation
- Swiss Cancer League (Krebsliga)
- UZH Entrepreneur Fellowship in Biotechnology
Ask authors/readers for more resources
The X-ray structure of the catalytic domain of the EphA3 tyrosine kinase in complex with a previously reported type II inhibitor was used to design two novel quinoxaline derivatives, inspired by kinase inhibitors that have reached clinical development. These two new compounds were characterized by an array of cell-based assays and gene expression profiling experiments. A global chemical proteomics approach was used to generate the drug-protein interaction profile, which suggested suitable therapeutic indications. Both inhibitors, studied in the context of angiogenesis andin vivoin a relevant lymphoma model, showed high efficacy in the control of tumor size.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available